IL240488A0 - Immunogenic composition for mers coronavirus infection - Google Patents

Immunogenic composition for mers coronavirus infection

Info

Publication number
IL240488A0
IL240488A0 IL240488A IL24048815A IL240488A0 IL 240488 A0 IL240488 A0 IL 240488A0 IL 240488 A IL240488 A IL 240488A IL 24048815 A IL24048815 A IL 24048815A IL 240488 A0 IL240488 A0 IL 240488A0
Authority
IL
Israel
Prior art keywords
immunogenic composition
coronavirus infection
mers coronavirus
mers
infection
Prior art date
Application number
IL240488A
Other languages
Hebrew (he)
Original Assignee
New York Blood Ct Inc
Shibo Jiang
Lanying Du
Guangyu Zhao
Yusen Zhou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Blood Ct Inc, Shibo Jiang, Lanying Du, Guangyu Zhao, Yusen Zhou filed Critical New York Blood Ct Inc
Publication of IL240488A0 publication Critical patent/IL240488A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
IL240488A 2013-03-01 2015-08-10 Immunogenic composition for mers coronavirus infection IL240488A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361771561P 2013-03-01 2013-03-01
US201461941076P 2014-02-18 2014-02-18
PCT/US2014/019402 WO2014134439A1 (en) 2013-03-01 2014-02-28 Immunogenic composition for mers coronavirus infection

Publications (1)

Publication Number Publication Date
IL240488A0 true IL240488A0 (en) 2015-09-24

Family

ID=51428838

Family Applications (1)

Application Number Title Priority Date Filing Date
IL240488A IL240488A0 (en) 2013-03-01 2015-08-10 Immunogenic composition for mers coronavirus infection

Country Status (4)

Country Link
US (1) US9889194B2 (en)
EP (1) EP2961768A4 (en)
IL (1) IL240488A0 (en)
WO (1) WO2014134439A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057942A1 (en) * 2013-10-18 2015-04-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (mers-cov) and engineered bispecific fusions with inhibitory peptides
WO2018094241A1 (en) * 2016-11-18 2018-05-24 New York Blood Center, Inc. Immunogenic composition for mers coronavirus infection
US11103575B2 (en) 2014-02-28 2021-08-31 The New York Blood Center, Inc. Immunogenic composition for MERS coronavirus infection
WO2016080591A1 (en) * 2014-11-17 2016-05-26 유한회사 바이오노트 Antibody recognizing nucleocapsid of middle east respiratory syndrome coronavirus, and use thereof
EP3227318A4 (en) * 2014-12-05 2018-12-12 Planet Biotechnology, Inc. Dpp4 immunoadhesin compositions and methods
NL2014148B1 (en) * 2015-01-16 2017-01-05 Univ Erasmus Med Ct Rotterdam Combination vaccine for camelids.
WO2016130838A1 (en) * 2015-02-11 2016-08-18 New York Blood Center, Inc. Porcine epidemic diarrhea virus immunogenic compositions
CN105273067A (en) * 2015-03-13 2016-01-27 中国疾病预防控制中心病毒病预防控制所 Recombinant 41-type adenovirus vector vaccine coding MERS-CoV spike protein
CN105543248A (en) * 2015-03-13 2016-05-04 中国疾病预防控制中心病毒病预防控制所 MERS-CoV spike protein coding gene optimization-based recombinant 5-type adenovirus vector vaccine
US10676511B2 (en) 2015-09-17 2020-06-09 Ramot At Tel-Aviv University Ltd. Coronaviruses epitope-based vaccines
WO2018097603A2 (en) * 2016-11-23 2018-05-31 에스케이케미칼 주식회사 Middle east respiratory syndrome coronavirus s protein immunogenic composition and method for preparing same
RO132299A3 (en) 2017-06-06 2018-12-28 Fântână Raul Sorin Composition and method for preparing and evaluating a complex immunogen named i-spga meant to produce immunologically active proteins
KR102103857B1 (en) * 2017-09-26 2020-04-27 한국생명공학연구원 Nc fusion protein comprising n-terminus domain fragments and c-terminus domain fragments of mers-cov nucleocapsid protein and kit for diagnosing infection of mers-cov using the same
KR102017217B1 (en) * 2017-10-19 2019-09-02 주식회사 엔케이맥스 An antibody against MERS-CoV and method of determining titration for antibody to MERS-CoV using the same
US11696948B2 (en) 2018-06-12 2023-07-11 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
AU2019286406B2 (en) 2018-06-12 2023-04-13 Kbio Holdings Limited Virus and antigen purification and conjugation
US11529413B2 (en) 2018-06-12 2022-12-20 Kbio Holdings Limited Virus and antigen purification and conjugation
US11690907B2 (en) 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
RU2709659C1 (en) * 2018-09-06 2019-12-19 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Immunobiological agent and a method for use thereof for inducing specific immunity to the middle eastern respiratory syndrome virus (versions)
US10849972B2 (en) 2018-11-27 2020-12-01 King Adulaziz University Trimeric S1-CD40L fusion protein vaccine against Middle East respiratory syndrome-coronavirus
CN111607002B (en) * 2020-02-24 2021-07-09 中山大学 Novel coronavirus S protein double-region subunit nano vaccine based on helicobacter pylori ferritin
CN111499765B (en) * 2020-04-08 2022-04-08 四川携光生物技术有限公司 Coronavirus fusion protein and preparation method and application thereof
EP4121105A4 (en) * 2020-04-21 2024-05-15 Kbio Holdings Ltd Vaccines formed by virus and antigen conjugation
WO2021225344A1 (en) * 2020-05-08 2021-11-11 한림대학교 산학협력단 Peptide for suppressing coronavirus and use thereof
CN113444155B (en) * 2020-05-18 2022-06-07 清华大学 MERS-CoV membrane protein receptor binding domain dimer, and coding gene and application thereof
US20220168276A1 (en) * 2020-08-05 2022-06-02 Tactical Therapeotics Inc. Mehods and Compositions for Treating SARS-CoV-2 Infection using Carboxyamidotriazole Orotate
KR20230054719A (en) * 2020-08-24 2023-04-25 사노피 파스퇴르 인크 Vaccine against SARS-CoV-2 infection
JP2023540778A (en) * 2020-09-07 2023-09-26 ジーアイ・セル・インコーポレイテッド Coronavirus-derived receptor binding domain mutant with reduced ACE2 binding ability and vaccine composition containing the same
CN114230674B (en) * 2020-12-01 2023-09-26 中国医学科学院基础医学研究所 Novel coronavirus S protein receptor binding domain fusion protein containing Fc domain and application thereof
CN112480268B (en) * 2020-12-10 2021-08-03 北京康乐卫士生物技术股份有限公司 Novel recombinant subunit vaccine of coronavirus and application thereof
US20220244257A1 (en) * 2021-01-29 2022-08-04 King Abdulaziz University Method for detection of mers-cov with igy antibodies
EP4313138A1 (en) 2021-03-30 2024-02-07 Viravaxx AG Sars-cov-2 subunit vaccine
GB202113559D0 (en) * 2021-09-23 2021-11-10 St Georges Hospital Medical School Fusion polypeptide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257852A1 (en) 2003-04-10 2006-11-16 Chiron Corporation Severe acute respiratory syndrome coronavirus
WO2005018538A2 (en) * 2003-06-04 2005-03-03 Vaxim, Inc. Severe acute respiratory syndrome (sars) polypeptides, antibodies to sars polypeptides and the use thereof in diagnostic, vaccination and therapeutic applications
US8936789B2 (en) 2008-10-16 2015-01-20 New York Bood Center, Inc. Immunoenhancer-linked oligomeric HIV envelope peptides
AU2010303568B2 (en) 2009-10-09 2014-07-31 New York Blood Center, Inc. Immunopotentiator-linked oligomeric influenza immunogenic compositions
KR20150064104A (en) 2012-09-23 2015-06-10 에라스무스 유니버시티 메디컬 센터 로테르담 Human Betacoronavirus Lineage C and Identification of N-terminal Dipeptidyl Peptidase as Its Virus Receptor
CN105025922B (en) 2013-01-31 2018-08-21 波特兰州立大学 Include the immunogenic composition and its application method of silication virus
CN103554235B (en) * 2013-06-17 2015-06-24 清华大学 RBD (receptor binding domain) segment in MERS-CoV (Middle East respiratory syndrome coronavirus) membrane protein and coding gene and application thereof
US9775894B2 (en) 2013-07-09 2017-10-03 University Of Washington Through Its Center For Commercialization Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
CA2922258C (en) 2013-09-19 2022-11-29 Novavax, Inc. Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods
US20160235837A1 (en) 2013-10-16 2016-08-18 Samuel Bogoch THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR MIDDLE EAST RESPIRATORY SYNDROME VIRUS (MERS CoV)
WO2015057942A1 (en) 2013-10-18 2015-04-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (mers-cov) and engineered bispecific fusions with inhibitory peptides
JP6412131B2 (en) 2013-11-29 2018-10-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア MERS-CoV vaccine

Also Published As

Publication number Publication date
US20160296617A1 (en) 2016-10-13
US9889194B2 (en) 2018-02-13
EP2961768A1 (en) 2016-01-06
EP2961768A4 (en) 2016-10-26
WO2014134439A1 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
IL240488A0 (en) Immunogenic composition for mers coronavirus infection
HK1231412A1 (en) Immunogenic composition
IL279395A (en) Vaccine composition
HK1212906A1 (en) Vaccine compositions
PL2647387T3 (en) Vaccine Composition
ZA201503927B (en) Immunogenic composition
SG11201404447WA (en) Immunogenic composition
IL237431A0 (en) Immunogenic compositions
IL238079A0 (en) Immunogenic composition
GB201223342D0 (en) Immunogenic composition
EP2979679A4 (en) Curable composition for dental use
EP2981529A4 (en) Oridonin analogs, compositions, and methods related thereto
IL243778A0 (en) Combination immunogenic compositions
HK1225306A1 (en) Dental composition
GB201218660D0 (en) Immunogenic composition
GB201313990D0 (en) Combination immunogenic compositions
GB201204968D0 (en) Immunogenic composition
GB201204851D0 (en) Immunogenic composition
EP2956112A4 (en) Dental composition
GB201318813D0 (en) Dental composition